المؤلفون: Gerber DE, Rasco DW, Le P, Yan J, Dowell JE, Xie Y, Gerber, David E, Rasco, Drew W, Le, Phat, Yan, Jingsheng, Dowell, Jonathan E, Xie, Yang

المصدر: Journal of Thoracic Oncology; 2011 Feb, Vol. 6 Issue 2, p365-371, 7p

المؤلفون: Keller PJ; Constellation Pharmaceuticals (United States), Cambridge, MA, United States., Adams EJ; Constellation Pharmaceuticals (United States), United States., Wu R; Constellation Pharmaceuticals (United States), Cambridge, Massachusetts, United States., Côté A; Ventus Therapeutics, Montreal, Quebec, Canada., Arora S; Transition Bio, Watertown, United States., Cantone N; Constellation Pharmaceuticals (United States), United States., Meyer R; Constellation Pharmaceuticals (United States), United States., Mertz JA; Flare Therapeutics, Inc., Cambridge, Massachusetts, United States., Gehling V; Constellation Pharmaceuticals (United States), United States., Cui J; Constellation Pharmaceuticals (United States), United States., Stuckey JI; Flare Therapeutics, Cambridge, Massachusetts, United States., Khanna A; Hansoh Bio, Rockville, Maryland, United States., Zhao F; Constellation Pharmaceuticals (United States), United States., Chen Z; Constellation Pharmaceuticals (United States), United States., Yu Z; Beth Israel Deaconess Medical Center, Boston, MA, United States., Cummings R; Constellation Pharmaceuticals (United States), Boston, MA, United States., Taimi M; Constellation Pharmaceuticals (United States), United States., Lakhani NJ; START Midwest, Grand Rapids, Michigan, United States., Rasco DW; South Texas Accelerated Research Therapeutics, San Antonio, TX, United States., Gutierrez M; Hackensack University Medical Center, Hackensack, NJ, United States., Duska L; University of Virginia School of Medicine, Charlottesville, Virginia, United States., Devitt M; University of Virginia School of Medicine, Charlottesville, Virginia, United States., Rippley R; Constellation Pharmaceuticals (United States), United States., Levell J; Constellation Pharmaceuticals (United States), United States., Truong J; Constellation Pharmaceuticals (United States), United States., Wang J; Myro Therapeutics, Watertown, Massachusetts, United States., Sun K; Constellation Pharmaceuticals (United States), Cambridge, Massachusetts, United States., Trojer P; TRIANA Biomedicines, Inc., Lexington, MA, United States.

المصدر: Cancer research [Cancer Res] 2024 Jun 04. Date of Electronic Publication: 2024 Jun 04.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

المؤلفون: Rasco DW; South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX, USA., Medina T; University of Colorado Cancer Center, Aurora, CO, USA., Corrie P; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Pavlick AC; Laura & Isaac Perlmutter Cancer Center at NYU Langone, New York, NY, USA., Middleton MR; Department of Oncology, NIHR Biomedical Research Centre, Oxford, UK., Lorigan P; The Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester, Manchester, UK., Hebert C; Bristol Haematology and Oncology Centre, Bristol, UK., Plummer R; The Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK., Larkin J; The Royal Marsden Hospital, London, UK., Agarwala SS; St. Luke's Cancer Center and Temple University, Easton, PA, USA., Daud AI; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA., Qiu J; Day One Biopharmaceuticals, 2000 Sierra Point Parkway, Suite 501, Brisbane, CA, 94005, USA., Bozon V; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Kneissl M; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Barry E; Day One Biopharmaceuticals, 2000 Sierra Point Parkway, Suite 501, Brisbane, CA, 94005, USA. elly.barry@dayonebio.com., Olszanski AJ; Fox Chase Cancer Center, Philadelphia, PA, USA.

المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2023 Jul; Vol. 92 (1), pp. 15-28. Date of Electronic Publication: 2023 May 23.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms*/pathology , Melanoma*/pathology , Skin Neoplasms*/pathology , Neoplasms, Second Primary*, Adult ; Humans ; Proto-Oncogene Proteins B-raf/genetics ; Protein Kinase Inhibitors ; Mitogen-Activated Protein Kinase Kinases ; Maximum Tolerated Dose

المؤلفون: Patnaik A; South Texas Accelerated Research Therapeutics, San Antonio, TX 78229, USA., Hamilton E; Breast and Gynecologic Research Program, Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville, TN 37203, USA., Xing Y; Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA., Rasco DW; South Texas Accelerated Research Therapeutics, San Antonio, TX 78229, USA., Smith L; South Texas Accelerated Research Therapeutics, San Antonio, TX 78229, USA., Lee YL; Fosun Pharma USA Inc., Lexington, MA 02421, USA., Fang S; Fosun Pharma USA Inc., Lexington, MA 02421, USA., Wei J; Fosun Pharma USA Inc., Lexington, MA 02421, USA., Hui AM; Fosun Pharma USA Inc., Lexington, MA 02421, USA.

المصدر: Cancers [Cancers (Basel)] 2022 Oct 12; Vol. 14 (20). Date of Electronic Publication: 2022 Oct 12.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

المؤلفون: LoRusso P; Yale Cancer Center, New Haven, CT, USA., Ratain MJ; University of Chicago, Chicago, IL, USA., Doi T; National Cancer Center Hospital East, Kashiwa, Japan., Rasco DW; START, San Antonio, TX, USA., de Jonge MJA; Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Moreno V; START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain., Carneiro BA; Lifespan Cancer Institute, Cancer Center at Brown University, Providence, RI, USA., Devriese LA; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Petrich A; AbbVie Inc, North Chicago, IL, USA., Modi D; AbbVie Inc, North Chicago, IL, USA., Morgan-Lappe S; AbbVie Inc, North Chicago, IL, USA., Nuthalapati S; AbbVie Inc, North Chicago, IL, USA., Motwani M; AbbVie Inc, North Chicago, IL, USA., Dunbar M; AbbVie Inc, North Chicago, IL, USA., Glasgow J; AbbVie Inc, North Chicago, IL, USA., Medeiros BC; AbbVie Inc, North Chicago, IL, USA., Calvo E; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain. emiliano.calvo@startmadrid.com.

المصدر: Investigational new drugs [Invest New Drugs] 2022 Aug; Vol. 40 (4), pp. 762-772. Date of Electronic Publication: 2022 Apr 25.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/adverse effects , Neoplasms*/metabolism, Dose-Response Relationship, Drug ; Fatigue/chemically induced ; Humans ; Maximum Tolerated Dose ; Nausea/chemically induced

المؤلفون: Patnaik A; START, 4383 Medical Drive, Suite 4026, San Antonio, TX, 78229, USA. amita.patnaik@startsa.com., Gadgeel S; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.; Henry Ford Health System, Detroit, MI, USA., Papadopoulos KP; START, 4383 Medical Drive, Suite 4026, San Antonio, TX, 78229, USA., Rasco DW; START, 4383 Medical Drive, Suite 4026, San Antonio, TX, 78229, USA., Haas NB; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Der-Torossian H; Mirati Therapeutics Inc., San Diego, CA, USA., Faltaos D; Mirati Therapeutics Inc., San Diego, CA, USA.; Olema Therapeutics, San Francisco, CA, USA., Potvin D; Mirati Therapeutics Inc., San Diego, CA, USA., Tassell V; Mirati Therapeutics Inc., San Diego, CA, USA., Tawashi M; Mirati Therapeutics Inc., San Diego, CA, USA.; HUYABIO International, San Diego, CA, USA., Chao R; Mirati Therapeutics Inc., San Diego, CA, USA., O'Dwyer PJ; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.

المصدر: Targeted oncology [Target Oncol] 2022 Mar; Vol. 17 (2), pp. 139.

نوع المنشور: Published Erratum

بيانات الدورية: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: PubMed not MEDLINE; MEDLINE

المؤلفون: Patnaik A; START, 4383 Medical Drive, Suite 4026, San Antonio, TX, 78229, USA. amita.patnaik@startsa.com., Gadgeel S; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.; Henry Ford Health System, Detroit, MI, USA., Papadopoulos KP; START, 4383 Medical Drive, Suite 4026, San Antonio, TX, 78229, USA., Rasco DW; START, 4383 Medical Drive, Suite 4026, San Antonio, TX, 78229, USA., Haas NB; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Der-Torossian H; Mirati Therapeutics Inc., San Diego, CA, USA., Faltaos D; Mirati Therapeutics Inc., San Diego, CA, USA.; Olema Therapeutics, San Francisco, CA, USA., Potvin D; Mirati Therapeutics Inc., San Diego, CA, USA., Tassell V; Mirati Therapeutics Inc., San Diego, CA, USA., Tawashi M; Mirati Therapeutics Inc., San Diego, CA, USA.; HUYABIO International, San Diego, CA, USA., Chao R; Mirati Therapeutics Inc., San Diego, CA, USA., O'Dwyer PJ; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.

المصدر: Targeted oncology [Target Oncol] 2022 Mar; Vol. 17 (2), pp. 125-138. Date of Electronic Publication: 2022 Mar 28.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Neoplasms*/drug therapy , Neoplasms*/pathology, Benzeneacetamides ; Docetaxel/pharmacology ; Docetaxel/therapeutic use ; Erlotinib Hydrochloride/pharmacology ; Erlotinib Hydrochloride/therapeutic use ; Humans ; Maximum Tolerated Dose ; Pyridines

المؤلفون: Patnaik A; South Texas Accelerated Research Therapeutics, San Antonio, TX, USA. Amita.Patnaik@startsa.com., Weiss GJ; Western Regional Medical Center, Cancer Treatment Centers of America, Goodyear, AZ, USA.; SOTIO, LLC, Cambridge, MA, USA., Rasco DW; South Texas Accelerated Research Therapeutics, San Antonio, TX, USA., Blaydorn L; Western Regional Medical Center, Cancer Treatment Centers of America, Goodyear, AZ, USA., Mirabella A; HonorHealth Research Institute/Translational Genomics Research Institute (TGen), Scottsdale, AZ, USA., Beeram M; South Texas Accelerated Research Therapeutics, San Antonio, TX, USA., Guo W; GlaxoSmithKline, Waltham, MA, USA., Lu S; GlaxoSmithKline, Waltham, MA, USA., Danaee H; GlaxoSmithKline, Waltham, MA, USA.; Blueprint Medicines, Cambridge, MA, USA., McEachern K; Ribon Therapeutics, Cambridge, MA, USA., Im E; GlaxoSmithKline, Waltham, MA, USA., Sachdev JC; HonorHealth Research Institute/Translational Genomics Research Institute (TGen), Scottsdale, AZ, USA.

المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Jan; Vol. 89 (1), pp. 93-103. Date of Electronic Publication: 2021 Nov 08.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized/*administration & dosage , Antibodies, Monoclonal, Humanized/*pharmacokinetics , Immune Checkpoint Inhibitors/*administration & dosage , Immune Checkpoint Inhibitors/*pharmacokinetics , Neoplasms/*drug therapy, Aged ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/pharmacology ; Area Under Curve ; Body Weight ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Immune Checkpoint Inhibitors/pharmacology ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplasms/pathology ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Treatment Outcome

المؤلفون: Perets R; Department of Oncology, Rambam Medical Center, Technion-Israel Institute of Technology, Haifa, Israel., Bar J; Cancer Center, Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel., Rasco DW; Phase I, START, San Antonio, USA., Ahn MJ; Department of Medicine, Samsung Medical Center, Sungkyunkwan University of Medicine, Seoul, South Korea., Yoh K; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Kim DW; Department of Hemato Oncology, Medical Oncology Center, and Personalized Cancer Medicine Center, Seoul National University Hospital, Seoul, South Korea., Nagrial A; Department of Cancer and Hematology, Blacktown Hospital and University of Sydney, Sydney, Australia., Satouchi M; Department of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan., Lee DH; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea., Spigel DR; Department of Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, USA., Kotasek D; Department of Medical Oncology, Adelaide Cancer Centre and University of Adelaide, Kurralta Park, Australia., Gutierrez M; Department of Hematology, Hematology Oncology, and Medical Oncology, Hackensack University Medical Center, Hackensack, USA., Niu J; Department of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, USA., Siddiqi S; MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA., Li X; MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA., Cyrus J; MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA., Chackerian A; Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, USA., Chain A; MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA., Altura RA; MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA., Cho BC; Division of Medical Oncology, Yonsei Cancer Center, Seoul, South Korea. Electronic address: CBC1971@yuhs.ac.

المصدر: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Mar; Vol. 32 (3), pp. 395-403. Date of Electronic Publication: 2020 Dec 02.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Lung Neoplasms*/drug therapy, Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Humans

المؤلفون: Tao JJ; Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Cangemi NA; Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Makker V; Gynecologic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Cadoo KA; Gynecologic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Liu JF; Dana-Farber Cancer Institute, Boston, Massachusetts., Rasco DW; South Texas Accelerated Research Therapeutics, San Antonio, Texas., Navarro WH; Atara Biotherapeutics, South San Francisco, California., Haqq CM; Atara Biotherapeutics, South San Francisco, California., Hyman DM; Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. hymand@mskcc.org.; Department of Medicine, Weill Cornell Medical College, New York, New York.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 Sep 15; Vol. 25 (18), pp. 5458-5465. Date of Electronic Publication: 2019 May 08.

نوع المنشور: Journal Article; Comment

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents* , Neoplasms* , Ovarian Neoplasms*, Activins ; Granulosa Cells ; Humans ; Maximum Tolerated Dose ; Treatment Outcome